Allergan Investors’ $130 Million Settlement Gets Final Court OK

Allergan PLC and investors who say the company misled them about generic drug competition and antitrust compliance secured final approval for their $130 million settlement from a federal judge in New Jersey.

The cash deal ends litigation alleging the pharmaceutical company touted competition while actually colluding with competitors to inflate generic drug prices. Allergan didn’t admit to any of the investor allegations as part of the settlement, the U.S. District Court for the District of New Jersey said.

Magistrate Judge Cathy L. Waldor in a separate order issued Monday awarded co-lead counsel Bernstein Litowitz Berger & Grossmann LLP and ...